BAY2416964

DRUG2 trials

Sponsors

Bayer

Conditions

Advanced Solid Tumors

Phase 1

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

CompletedNCT04069026

BayerAdvanced Solid Tumors

Start: 2019-08-15End: 2024-01-17Updated: 2024-03-06

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

TerminatedNCT04999202

BayerAdvanced Solid Tumors

Start: 2021-08-30End: 2025-01-20Updated: 2025-02-10

Related Papers

1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC

Regular and Young Investigator Award Abstracts2023-10-31

Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-0111 citations